Sterling Pharma Solutions has announced the acquisition of ADC Bio, a UK-based company that specializes in antibody drug conjugates. ADC’s Wales manufacturing facility will rebrand to become part of the Sterling network, the companies said.

ADC will start work as part of the Sterling network as early as 2022. The move allows Sterling to integrate the new facility’s highly potent API capabilities to develop and manufacture toxin linkers, according to a release.

The FDA on Thursday raised fresh quality concerns about Emergent BioSolutions’ manufacturing site in Baltimore, which has more recently been taken over by J&J after an error caused the site to discard about 15 million doses of the company’s vaccine last month.

According to a Form 483 issued to the contract testing lab last April, following a 7-day inspection and just released by the FDA, Emergent’s quality unit failed to ensure some very basic, fundamental activities, like that staff couldn’t just delete or manipulate electronic data, and the responsibilities and procedures for the quality unit were not in writing or fully followed, FDA said.

Another company has been forced to recall bottles of its product after a labeling misstep.

A-S Medication Solutions is voluntarily recalling 100 count bottles of its Acetaminophen Extra Strength 500 mg tablets after reports that the bottle contains an incomplete prescription drug label as opposed to the required over-the-counter drug facts label. The recall is expected to be on 198,350 bottles of the pain and fever reliever.

One of the big contract partners in the Covid-19 effort, Catalent has signed deals with most of the major vaccine players to help ramp up supply. Now, the New Jersey firm will expand its deal with Moderna in hopes of churning out double the amount of finished vials in time for summer.

The CDMO will increase its production capacity of the vaccine in its Bloomington, IN biologics facility through its new high-speed vial filling line, Catalent announced Tuesday. Sources close to the matter told The Wall Street Journal that agreement will increase the vaccine output in April to 400 vials a minute.

Since September 2019, 2,400 people with the rare condition known as hypoparathyroidism have been waiting for any sign that supplies of their reliable injection from Takeda might reemerge.

Last Wednesday, however, Takeda announced that supplies won’t be ready for at least another year, stranding those who still can’t access the drug, known as Natpara (parathyroid hormone), via the company’s Special Use Program (SUP), which is only for about 400 of those who are at extreme risk of life-threatening complications.

The FDA has authorized an Indiana CDMO to produce and ship millions of doses of J&J’s Covid-19 vaccine.

Catalent Pharma tweeted the news and an accompanying video from its Bloomington facility last week. The manufacturer received a EUA, which puts J&J a step closer toward meeting its goal of providing the US with 100 million doses by the end of June.

Today, Catalent is proud to share that our Bloomington, Indiana site’s recently completed expansion received Emergency Use Authorization from the FDA to produce and ship millions of doses of Johnson & Johnson’s COVID-19 vaccine. Learn more: https://t.co/jFg5OoWkyO @JNJNews pic.twitter.com/rDhSl8Uois

J&J has run into a snag in production of its Covid-19 vaccine after its quality patrol spotted problems with one batch of drug substance.

The issue — which the New York Times reported was due to a mix-up between the vectors used in J&J and AstraZeneca’s vaccines — sent J&J into trouble-shooting mode. The company said it’s sending additional experts in manufacturing, technical operations and quality to supervise onsite at Emergent’s Bayview facility, which was once touted for its capacity to rapidly scale manufacturing.